不孕症藥物市場規模、佔有率和成長分析：按藥物類型、適應症、應用、通路和地區分類－2026-2033年產業預測

2024 年全球不孕症治療市場價值 42.2 億美元，預計從 2025 年的 45 億美元成長到 2033 年的 75.2 億美元，預測期（2026-2033 年）的複合年成長率為 6.62%。

全球生育藥物市場是生殖醫學的關鍵領域，為患者和醫療專業人員提供必要的荷爾蒙療法和促排卵藥物。由於女性推遲生育的現象增多以及卵巢症候群等疾病的日益普遍，對生育藥物的需求正在激增。從廣泛用於女性的枸櫞酸氯米芬，到促性腺激素分泌和生物相似藥等創新治療方法，藥物研發都取得了顯著進展。影響市場成長的關鍵趨勢包括：生物相似藥提高了藥物的可近性和可負擔性；擴大了報銷範圍；以及分散式醫療模式的普及。這些趨勢提高了患者對治療的接受度，尤其是在亞洲和拉丁美洲等價格敏感地區；並使診所能夠透過個人化給藥方案來提升服務品質和增加產品供應。

全球不孕症治療市場的成長要素

隨著輔助生殖技術服務的擴展，不孕症藥物的需求顯著增加。這是因為診所需要多種藥物療法來促進卵巢刺激、黃體期維持和子宮內膜準備。隨著診所不斷完善服務並開發更全面的治療方案，醫療服務提供者越來越依賴成熟藥物和創新藥物來制定滿足各種患者需求的個人化治療方案。這種綜合臨床方法不僅鞏固了這些藥物的銷售，也促使藥廠拓展其不孕症產品線。因此，各種醫療服務模式對這些治療方法的依賴都在不斷增強，從而進一步擴大了市場機會。

全球不孕症治療市場的限制因素

全球生育藥物市場面臨許多限制因素，主要包括高昂的自付費用和複雜的報銷體系，這些因素阻礙了許多患者尋求生育治療。這種猶豫不決限制了參與藥物試驗和使用藥物的患者人數，因為經濟方面的考慮往往導致醫療專業人員建議強度較低的療法或非藥物治療方法。因此，患者可能完全推遲就醫。生育治療的可及性有限是市場擴張的主要障礙，它縮小了潛在的消費群體，阻礙了對分銷和支持服務的投資，並為生育藥物在臨床環境中的廣泛應用帶來了挑戰。

全球不孕症治療市場趨勢

全球生育藥物市場正經歷著向個人化治療的顯著轉變，強調根據每位患者獨特的荷爾蒙和基因特徵量身定做的個人化治療方法。這一趨勢促進了製藥公司與生育診所之間的合作，從而催生出更貼合患者需求的個人化給藥策略和客製化給藥方式。製造商正利用這一趨勢，透過靶向配方和服務實現產品差異化，並鼓勵患者長期堅持治療。此外，以價值為導向的夥伴關係優先考慮臨床療效和患者滿意度，推動商業性活動朝向整合式醫療模式發展，從而提升生育領域的整體治療效果和患者體驗。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球不孕症治療藥物市場規模：依藥物類型分類

• 促性腺激素
• GnRH促效劑和拮抗劑
• 枸櫞酸氯米芬
• 黃體素製劑
• 其他

全球不孕症治療藥物市場規模：依適應症分類

• 女性不孕症
• 男性不孕

全球不孕症治療藥物市場規模：依應用領域分類

• 體外受精（ART）
• 誘導排卵

全球不孕症治療藥物市場規模：按分銷管道分類

• 醫院藥房
• 專科診所
• 線上

全球不孕症治療藥物市場規模：按地區分類

• 北美洲
• 歐洲
• 亞太地區

全球不孕症治療藥物市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Merck KGaA（Gonal-F）
• Ferring Pharmaceuticals
• IBSA Pharma
• Organon & Co.
• EMD Serono（Merck）
• Abbott Laboratories
• Pfizer Inc.
• Sun Pharmaceutical
• Dr. Reddy's Laboratories
• MSD（Merck）
• Gedeon Richter
• BioSig Technologies
• Theramex Group
• Lumenis Ltd.
• Besins Healthcare

結論與建議

Global Infertility Drugs Market size was valued at USD 4.22 Billion in 2024 and is poised to grow from USD 4.5 Billion in 2025 to USD 7.52 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026-2033).

The global infertility drugs market represents a vital segment within reproductive health, offering vital hormone therapies and ovulation stimulants to patients and healthcare providers. With more women delaying motherhood and an increase in conditions such as polycystic ovary syndrome, the demand for fertility medications has surged. Significant advancements have been made in drug development, transitioning from clomiphene citrate, widely used by women, to innovative treatments like gonadotropins and biosimilars. Key trends influencing growth include enhanced accessibility and affordability through biosimilars, expanded reimbursement options, and decentralized care models. These trends have boosted patient treatment uptake, particularly in price-sensitive regions like Asia and Latin America, and have allowed clinics to enhance services while increasing product availability through tailored dosing solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infertility Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infertility Drugs Market Segments Analysis

Global infertility drugs market is segmented by drug type, indication, application, distribution and region. Based on drug type, the market is segmented into Gonadotropins, GnRH Agonists & Antagonists, Clomiphene Citrate, Progesterone Supplements and Others. Based on indication, the market is segmented into Female Infertility and Male Infertility. Based on application, the market is segmented into IVF (ART) and Ovulation Induction. Based on distribution, the market is segmented into Hospital Pharmacies, Specialty Clinics and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infertility Drugs Market

The growth of assisted reproductive services has significantly heightened the demand for infertility drugs, as clinics necessitate a variety of pharmacological options to facilitate controlled ovarian stimulation, luteal support, and endometrial preparation. As clinics enhance their service offerings and formulate more comprehensive treatment pathways, healthcare providers increasingly depend on both established and innovative medications to tailor protocols for a wide range of patient needs. This integrated clinical approach not only solidifies the purchase of these drugs but also motivates pharmaceutical companies to enhance their infertility product lines. As a result, there is a growing reliance on these therapies across various healthcare delivery models, further expanding market opportunities.

Restraints in the Global Infertility Drugs Market

The Global Infertility Drugs market faces significant constraints primarily due to high out-of-pocket expenses and convoluted reimbursement systems, which deter many patients from pursuing infertility treatment. This hesitance restricts the number of individuals engaging in drug studies or using medications, as financial concerns often lead healthcare providers to recommend less intensive or non-pharmaceutical alternatives. Consequently, patients may postpone seeking care altogether. This limited access to infertility treatments creates considerable obstacles that hinder market expansion by reducing the potential consumer base, discouraging investment in distribution and support services, and posing challenges to the widespread acceptance of infertility drug therapies within clinical settings.

Market Trends of the Global Infertility Drugs Market

The Global Infertility Drugs market is experiencing a notable shift towards personalized care pathways, emphasizing individualized treatment regimens that cater to patient-specific hormonal and genetic profiles. This trend is fueling collaboration between pharmaceutical developers and fertility clinics, leading to tailored dosing strategies and customized drug delivery methods that align closely with patient needs. Manufacturers are leveraging this movement to differentiate their offerings through targeted formulations and services, fostering long-term treatment adherence. Moreover, the focus on value-based partnerships prioritizes clinical outcomes and patient satisfaction, driving commercial efforts toward integrated care models that enhance overall treatment efficacy and patient experience in the infertility landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Infertility Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Gonadotropins
• GnRH Agonists & Antagonists
• Clomiphene Citrate
• Progesterone Supplements
• Others

Global Infertility Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Female Infertility
• Male Infertility

Global Infertility Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• IVF (ART)
• Ovulation Induction

Global Infertility Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Clinics
• Online

Global Infertility Drugs Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Infertility Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Indication, Application, Distribution, Region)
  • US
  • Canada
• Europe (Drug Type, Indication, Application, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Indication, Application, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Indication, Application, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Indication, Application, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck KGaA (Gonal-F)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBSA Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono (Merck)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD (Merck)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSig Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theramex Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Besins Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations